

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number  
**WO 02/102410 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 39/39**,  
39/12, C12N 15/82, A01H 5/00, A61P 31/00

(21) International Application Number: PCT/IT02/00354

(22) International Filing Date: 31 May 2002 (31.05.2002)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:  
RM2001A000332 11 June 2001 (11.06.2001) IT

(71) Applicants (for all designated States except US): **ENTE PER LE NUOTE TECNOLOGIE L'ENERGIA E L'AMBIENTE (ENEA)** [IT/IT]; Lungotevere Thaon di Revel 76, I- 00196 Roma (IT). **ISTITUTO SUPERIORE DI SANITÀ** [IT/IT]; Viale Regina Elena, 299, I-00161 Rome (IT). **ISTITUTI FISIOTERAPICI OSPITALIERI (IFO) ISTITUTO REGINA ELENA** [IT/IT]; Per lo studio e la cura dei tumori, Via Elio Chianesi 53, I-00128 Roma (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRANCONI, Rosella** [IT/IT]; Via Aldo Moro 9, I-00061 Anguillara Sabazia RM (IT). **GIORGI, Colomba** [IT/IT]; Viale Giulio Cesare, I-00192 Roma (IT). **VENUTI, Aldo** [IT/IT]; Piazza Ippolito Nievo 21, I- 00153 Roma (IT). **MARCANTE, Maria-Luisa** [IT/IT]; Via Bolsena 27, I-00191 Roma (IT). **ACCARDI, Luisa** [IT/IT]; Via Molveno 36, I- 00135 Roma (IT). **DI BONITO, Paola** [IT/IT];

Piazza dei Consoli 11, I-00175\_Roma (IT). **DIBELLO, Francesco** [IT/IT]; Via L. Tolstoj 7/B, I-00061 Anguillara Sabazia RM (IT). **BITTI, Orsola** [IT/IT]; Via Roma 5, I-01010 Veiano VT (IT).

(74) Agents: **GERMINARIO, Claudio** et al.; Società Italiani Brevetti, Piazza di Pietra, 39, I-00186 Roma (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBUNIT VACCINES AND PROCESSES FOR THE PRODUCTION THEREOF

(57) Abstract: The present invention refers to the use of an extract of soluble proteins from plant leaf cells for the preparation of subunit vaccines comprising said extract as adjuvant, to the vaccines and to the kit comprising said extract as adjuvant and to the processes for the preparation thereof. the present invention further refers to a plant obtainable by the step of expressing in soluble from a protein antigen in leaf cells at a concentration greater than or equal to 3 µg of protein per gram of leaf.

WO 02/102410 A1

SUBUNIT VACCINES AND PROCESSES FOR THE PRODUCTION THEREOF  
DESCRIPTION

Field of the Invention

5 The present invention refers to the field of immunology and in particular to the sector of the so-called subunit vaccines.

State of the Art

Subunit vaccines are known to the art.

10 Those are vaccines comprising as immunogen specific macromolecules (vaccinogens) able to induce a protective immune response towards a certain pathogen, or a certain tumour-associated antigen. In particular, among the vaccinogens used in the art, there are molecules of protein nature derived from pathogens, like, e.g.,  
15 viruses or bacteria, per se not able to determine the onset of the illness.

Therefore, such vaccines allow vaccination strategies which are safer with respect to those proper of the traditional vaccines, based on whole, killed or  
20 inactivated pathogens.

However, with respect to the former, the subunit vaccines present a first problem resulting from the fact that the vaccinogens used in the art are molecules that per se generally exhibit scarce or even absent  
25 immunogenicity.

In order to overcome this problem, the subunit vaccines often comprise, or are administered along with, adjuvants, i.e., substances able to increase the immunogenicity of the utilized vaccinogen when  
30 administered therewith, whose action mechanisms are still not completely known.

Among all known adjuvants, the aluminum-based mineral salts (alum) and the MF59 are the only ones demonstrated to be safe enough to be approved for human  
35 use. However, aluminum is a weak adjuvant for antibody induction and for cell-mediated immunity response in the case of subunit protein-based vaccines.

Research on adjuvants is presently very active, also due to the development of new-generation vaccines (e.g. recombinant and mucosal vaccines).

5 The effectiveness of these adjuvants is evaluated from the presence of helper and cytotoxic lymphocyte clones, from the presence of some immunoglobulin classes (e.g. IgG<sub>2</sub>) and of Th1-type cytokines, upon administration of vaccines containing them. Particularly effective are considered the adjuvants able to elicit a  
10 humoral as well as a cell-mediated response (like, e.g., the Quil-A, at least in the experimental animal).

Additionally to adjuvant effectiveness, a further relevant parameter in the study and development of the adjuvants is that of their safety. In clinical trials,  
15 many experimental adjuvants are used. Though some of the latter could be employed in those applications (like anti-cancer therapy) in which a certain level of side effects is tolerable, most of them are too toxic for routine clinical use.

20 A second problem of the subunit vaccines is that of their storage, particularly in all those cases in which the vaccinogens are molecules of protein nature, hence exhibiting all the problems related to the storage of purified proteins with the related instability and  
25 thermolability of the vaccine compositions.

A third problem of the subunit vaccines is related to their production in industrially relevant quantities. Once the vaccinogen is identified, the process leading to its production generally comprises the isolation of the  
30 corresponding gene and the its expression in a heterologous system. However, the systems used in the art do not always allow to produce the vaccinogen in native form, and often entail low yields and rapid degradation, with generally lengthy and costly purification  
35 procedures.

Subunit vaccines representative of the problems highlighted above are those comprising the E7 protein of

the human papillomavirus (HPV), per se scarcely immunogenic and highly unstable.

In fact, the HPV E7 protein exhibits a low half-life in vivo (about 30-40 min, after 1 hour about 70% of the protein is degraded) (Reinstein E, Scheffner M, Oren M et al (2000). 'Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue'. *Oncogene* 19: 5944-5950). The instability also characterises the recombinant E7 protein purified from eukaryotic expression systems (yeast, insect) or from bacteria, used in clinical trials of therapeutic vaccines.

Attempts at purifying large quantities of E7 protein not fused to other proteins or peptides led to very low yields, due to a rapid proteolytic degradation.

#### Summary of the invention

Object of the present invention is to provide subunit vaccines allowing to overcome at least one of the drawbacks highlighted above and therefore be immunogenic, stable and/or produced by procedures quicker and simpler with respect to those proper of the state of the art.

According to a first aspect of the invention, this object is attained by the use of an extract of soluble proteins from leaf cells of a plant selected from the group comprising *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*, preferably *Nicotiana benthamiana*, for the preparation of subunit vaccines comprising this extract as adjuvant along with a vaccinogen of interest, and by subunit vaccines comprising said extract.

Actually, the main advantage of the subunit vaccines of the invention ensues from the ability of the foliar cell extract of acting as adjuvant. In fact, this extract is able to increase the immunogenicity of a vaccinogen of interest, until enabling the latter to induce immune response oa humoral as well as a cell-mediated immune response, in a way in all comparable to that of adjuvants like the Quil-A. This is so particularly in the case of

vaccinogens consisting of antigens of viral nature like the E7 protein of the human papillomavirus (HPV).

Consequently to the adjuvanting ability of the abovementioned extract, the resulting vaccine can be administered even without added adjuvant and it can protect against tumour development in animal models.

The foliar cell extract of *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*, can be obtained according to the invention by adopting the extraction procedures known to a person skilled in the art and determinable by the former on the basis of the information provided in the present patent application and in the documents cited therein. However, it has to be highlighted that to the ends of the invention the use in the extraction procedures and, accordingly, the presence of protease inhibitors in the extract, does not affect the functionalities of the extract\_itself.

A person skilled in the art will also be aware of the modes of combining the vaccinogen, in a preferred embodiment consisting of the HPV E7 protein, and the extract in the same vaccine composition. The skilled person may single out said modes in the light of what is reported in the present application and in the cited documents.

In a particularly preferred embodiment, said combining is carried out by means of a process for producing a subunit vaccine, it also object of the invention, comprising the steps of:

a. expressing in soluble form a protein antigen in leaf cells of a plant selected from a group comprising *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*, preferably *Nicotiana benthamiana*, at a concentration greater than or equal to 3  $\mu$ g of protein per gram of leaf; and

b. preparing an extract of total soluble proteins from said cells; said plant extract being useful as subunit vaccine.

A first advantage associated to this process lies in the possibility to obtain thereby the vaccinogen in native form comprised in extracts directly useful to immunize an animal or a human being.

5 A second advantage of the process of the invention lies in that said vaccinogen-containing extract can be obtained in quantities suitable to the administration for immunogenic purposes within a very short time (1-2 weeks).

10 A third advantage of the invention lies in that such extract is able to elicit a Th1-type and a Th2-type immune response, hence being useful for both prophylactic and therapeutic vaccines.

A further advantage of the invention lies in that  
15 the antigen-containing plants of *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*, (in particular those of *Nicotiana benthamiana*), also object of the invention as obtainable by the above step a., can be stored at room temperature, whereas the vaccine  
20 composition comprising said extract is stable at +4°C.

In a preferred embodiment, the concentration of which at step a. is reached by transfection with a plant vector, in particular with a viral vector which in a more preferred embodiment is derived from the potato virus X  
25 (PVX).

Concerning step b., it should be carried out by passages finally yielding an extract free from substances injurious to the organism to which the vaccine is destined.

30 Thus, in a preferred embodiment, step b. can advantageously be carried out using techniques known in the art to extract total soluble proteins directly in the absence of detergents and of denaturing substances, determinable by a person skilled in the art in the light  
35 of the present application and of the documents cited herein. However, as abovementioned, the use of protease inhibitors is unnecessary to the ends of the invention.

Through the process of the invention extracts can be produced comprising any one vaccinogen of protein nature of known nucleotide and/or amino acid sequence.

Among the preferred vaccinogens there are those  
5 consisting of a viral antigen, which in a particularly preferred embodiment is provided by the E7 protein of the HPV virus. In fact, this embodiment is particularly preferred in the light of the scarce immunogenicity and of the instability exhibited by said protein per se in  
10 the absence of adjuvants.

Thus, the vaccine produced according to the abovedescribed process of the invention constitutes a preferred embodiment of the subunit vaccine of the invention. This is so since the vaccinogens comprised in  
15 the vaccine, and in particular the vaccinogen of viral nature like the E7 protein of the HPV16, perform their full immunogenic action above all when synthetized by the plant from which the extract is prepared.

In the light of the above, object of the invention  
20 is also the use of the vaccine of the invention for the treatment of pathologies for the therapy of which it is necessary or advisable to induce an immune response of a humoral as well as of a cell-mediated type towards a determined antigen, such as, in particular, infections  
25 from viruses, bacteria or other microorganisms and from tumour-associated antigens.

The ability to induce a cell-mediated response renders the use of the vaccinal preparation of the invention particularly expedient in the treatment of all  
30 those pathologies whose therapy requires a modification of the immune response, such as tumours or autoimmune diseases.

Alternatively to the embodiment of the invention in which extract and vaccinogen are comprised in an  
35 individual vaccinal preparation prepared in any which way, the extract of the invention and the vaccinogen of interest (included in a composition comprising the

vaccinogen and the compatible adjuvants) can be comprised in a kit for the treatment of the aboveindicated pathologies which comprises them for concomitant, sequential or separated use in the treatment of said pathologies.

In particular, the vaccinogen comprised in said kit can be obtained according to the process disclosed hereinafter.

In fact, according to a further aspect of the invention, the above described object is also attained by a process for the production of a vaccinogen comprising the steps a. and b. of the abovedescribed process and the further step of

c. purifying said vaccinogen from said extract.

In fact, the vaccinogen thus produced can expediently be used for the preparation of a vaccine for the treatment of a pathology associated to the accumulation of the antigen corresponding to said vaccinogen.

In this embodiment the vaccinogen should anyhow be administered along with an adjuvant, though its use upon purification from plant extracts provides procedures which are simpler, faster and safer with respect to those known in the art for vaccinogen production.

Moreover, the vaccinogen thus produced is advantageously expressed in its entirety, hence providing all of its antigenic determinants, at high levels and in a stable form in plant extracts stored at 4°C for more than 10 days.

In the light of the above, a further object of the present invention are plant preparations of antigens to be used in animals for the production of immune sera and of specific immunoglobulins.

In this case, the outcome of the purification process, object of the invention, followed by the process for the production of sera in animals, leads to the production of hyperimmune sera against gene products of



which a mere fraction of the nucleotide sequence and not the natural protein is known.

Moreover, the abovementioned production procedure provides remarkable features of stability.

5 As aboveanticipated, a further object of the invention are the plants obtainable by step a. of the process of the invention, in particular *N. benthamiana* infected by a vector, preferably consisting of the vector PVX, comprising the sequence coding for the E7 protein.

10 Particularly preferred is a plant having a foliar tissue with symptoms of infection, a high expression level of the heterologous protein being associated thereto.

Hereinafter, the invention will be described making  
15 reference to the attached Figures.

#### Description of the Figures

Figure 1 is a schematic representation of the vector pPVX201-E7, derived from PVX genome, used for the transient expression of the gene encoding the E7  
20 oncoprotein of the human papillomavirus 16 (HPV16) in plants.

The term CaMV35S indicates the promoter 35S of the cauliflower mosaic virus; the term 166 K indicates the gene encoding the protein required for PVX replication;  
25 the terms 25 K, 12 K, 8 K indicate the three partially overlapped 'open reading frames', coding for the 25, 12 and 8 KDa PVX proteins, respectively; the term CP indicates the gene for the PVX coat protein; the term NOS-ter indicates the transcription termination signal  
30 derived from the nopaline synthase gene of *Agrobacterium tumefaciens*; the terms ClaI, SalI, indicate the restriction enzymes cleavage sites located at the cloning sites of the heterologous gene.

Figure 2 shows the result of an immunoblot (Western  
35 blot) assay of the proteins extracted from plants of *Nicotiana benthamiana* infected with PVX201-E7 (plasmid or virion, 7 days post-inoculation).

Numbers 1 and 2, indicate the lanes loaded, respectively, with 15 and 30  $\mu\text{g}$  of total soluble proteins from unfiltered leaf extracts deriving from PVX201-E7 infected plants. Numbers 3 and 4, indicate the lanes loaded, respectively, with 15 and 30  $\mu\text{g}$  of total soluble proteins from leaf extracts, filtered with a 0.22  $\mu\text{m}$  filter, deriving from PVX201-E7 infected plants. Number 5 indicates the lane loaded with 20  $\mu\text{g}$  of total soluble proteins from leaves of wild type PVX-infected plants. Number 6 indicates the lane loaded with the molecular weight marker for proteins. Numbers 7, 8, 9, and 10, indicate the lanes loaded, respectively, with 67, 40, 26, 13 ng of His-E7 protein purified by *E. coli*.

Figure 3 is a diagram illustrating the detection of the E7 protein in PVX201-E7-infected *N. benthamiana* plants by TAS ('triple antibody sandwich')-ELISA. On the y-axis the absorbance values are reported, whereas on the x-axis the extracts to which said values are referred are reported.

In particular, number 1 on the x-axis indicates the histogram related to extracts of PVX201-E7-infected plants; number 2 on the x-axis indicates the histogram related to extracts, filtered with a 0.22  $\mu\text{m}$  filter, of PVX201-E7 infected plants; number 3 on the x-axis indicates the histogram related to extracts of wild type PVX201 infected plants; number 4 on the x-axis indicates the histogram related to 600 ng of His-E7 protein purified by *E. coli*.

Figure 4 is a diagram illustrating the ELISA reactivity of sera of mice immunized with the extracts of the invention. On the y-axis the relative reactivity of the anti-E7 IgG, and on the x-axis the proteins or the extracts to which said reactivity refers are reported.

In particular, the samples of sera of animals vaccinated with the plant extracts containing the native E7 protein are marked by the symbol  $\square$ , the sera of animals vaccinated with foliar extract to which the

recombinant His-E7 protein obtained in *E.coli* had been added is marked by the symbol  $\nabla$  and, finally, the control animals vaccinated with the recombinant His-E7 protein and the adjuvant Quil-A are marked by the symbol  
5 O. The value of the preimmunized sera increased of two times the standard deviation was taken as cutoff value of the sera and it is depicted as a broken line in the graph. All the animals were vaccinated subcutaneously with the same vaccination scheme.

10 Figure 5 shows the scheme for an experimental vaccination in animal model (mouse).

Detailed description of the invention

His-E7 protein, produced by *E. coli* and purified according to standard procedures, was added to plant  
15 extracts derived from *Nicotiana benthamiana* prepared according to the processes described hereinafter.

This mixture was administered to mice for vaccination purposes along with the preparation described hereinafter.

20 As it is reported in the summary of the invention, in a preferred embodiment antigen and adjuvanting extract are combined by a process of in-plant production of heterologous antigens through infection with vectors of viral origin (in plasmid form or as virions contained in  
25 plant juices). In particular, the gene encoding the E7 oncoprotein was amplified from a plasmid containing the genome of the human papillomavirus 16 (HPV16) by PCR (polymerase chain reaction) and cloned in a vector derived from the potato virus X (PVX) for the transient  
30 expression in-plant.

However, it should be highlighted that in the abovementioned process there may be used all the plant viruses belonging to the potexvirus genus, and in general all the vectors known to the art useful for the  
35 transfection of *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*, in particular any virus able to infect such a plant and potentially non-injurious to the

subjects to be immunized (a limitation superfluous in case the vaccinogen should be purified by usual processes).

5 Viral vectors, by virtue of their features (multiplication rate, absence of pathogenicity in humans, stability at room temperature, etc.) are a particularly effective tool for the in-plant expression of heterologous proteins.

10 However, in order to obtain vaccinogen-containing extracts, also bacterial vectors (like, e.g. *Agrobacterium tumefaciens*) are useful, which can be employed both for transient expression by agroinfiltration, and to obtain stable expression through the production of transgenic plants. Likewise, 15 physical and/or chemical transformation systems are useful (e.g., a biolistic system or by polyethylene glycol, PEG) with which not only the main nuclear genome but also that of the plastids (e.g., chloroplast) can be genetically transformed. These systems, alternative to 20 the transformation of the nuclear genome, can greatly enhance the expression level of the heterologous protein.

Hence, the use of viral vectors and in particular of the PVX vector detailed hereinafter merely constitutes a particularly preferred embodiment.

25 Also the selection of the antigen produced in the model system (the E7 protein, whose gene was cloned starting from the codon encoding the first methionine, to produce a 98-aa protein) was performed, as this protein, by virtue of its features, is representative of the 30 vaccinogens particularly suitable to be used in the processes and for the vaccine compositions of the invention.

Said protein is recognised as tumour antigen of the HPV-associated cervical carcinoma, and therefore as a 35 putative vaccinogen for stimulating an immune response aimed at curing the tumour. Moreover, said protein is per se scarcely immunogenic and highly unstable and it

requires the adding of adjuvants in order to induce a cell-mediated immune response (see state of the art above). Through the inventive process, the E7 protein results in an already adjuvated form enabling it to  
5 elicit a valid therapeutic response.

However, other antigens are likewise useful to the ends of the invention, in particular those having analogous features with respect to E7.

Hence, in particular the antigens useful in the  
10 process of the invention comprise viral and bacterial pathogenic proteins.

In fact, by the process of the invention it is possible to produce extracts comprising any one  
15 vaccinogen of protein nature of known nucleotide and/or amino acid sequence. Therefore, in particular there are comprised the pathogen-derived vaccinogens in general or associated to specific pathologies, like, e.g., viral or bacterial pathologies, or pathologies anyhow associated to the presence of microorganisms, and several tumour  
20 forms, (e.g., tumour-associated antigens) or pathologies caused by or anyhow associated to the presence of specific molecules.

Particularly suitable to be utilized in this procedure are viral antigens having well-known  
25 immunological features, and hence identifiable as putative vaccinogens. An exemplary virus is the human papillomavirus (HPV). In fact, HPV genome expresses only 8 proteins whose specific function is still not completely clear, including the abovementioned E7  
30 protein.

The gene constructs of interest in the process of the invention generally comprise, besides all the functions required for PVX replication (genes 166, 25, 12  
8 K and CP) a duplicated promoter for the gene of the  
35 virus-coat protein, so as to allow the expression of a soluble protein (see Figure 1).

Said constructs can comprise the gene of interest operatively linked to a signal sequence allowing to vehicle the protein in the secretory route and in the apoplast of the plant cell, and therefore to obtain a more concentrated and, possibly, stabler product.

Moreover, at the carboxy- or amino- terminal of the protein tags can advantageously be added which may be useful in troublesome native protein purifications.

Tags useful for said purpose are the c-myc tag and the flag tag, against which specific monoclonal antibodies for immune purification or a poly-histidine tail (His6) for purification by IMAC (Immobilized-metal affinity chromatography) are available.

Plasmid pPVX201-E7 proved particularly advantageous as a vector (Figure 1). This vector derives from plasmid pPVX201 (Baulcombe D. C., Chapman S., Santa Cruz S. (1995). 'Jellyfish green fluorescent protein as a reporter for virus infections'. *The Plant Journal* 7: 1045-1053), in turn derived from vector pGC3 (Chapman S., Kavanagh T., Baulcombe D. (1992). 'Potato virus X as a vector for gene expression in plants'. *The Plant Journal* 2: 549-557). The former contains unique sites for the cloning of the heterologous gene downstream of the duplicated promoter for the subgenomic RNA of the PVX coat protein, and it allows to infect plants directly with the plasmid DNA, since the entire PVX genome is controlled by the 35S promoter of the cauliflower mosaic virus (CaMV).

Concerning the plant host, as aboveresported, the transfection was conducted in *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa* plants.

Upon infection of *N. benthamiana* with pPVX201-E7, the symptoms of PVX infection generally appear 6-7 after inoculation, along with the expression of soluble E7 as vaccinogen of interest.

Significant amounts of E7 protein were detected in leaf extracts of plants infected with a vector pPVX201-E7

(for simplicity hereinafter referred to as PVX-E7), in particular both in the inoculated leaves and in the apical ones with symptoms of infection. This was assayed by Western blot, in which a mouse polyclonal antibody  
5 against the recombinant E7 protein produced in *E. coli* (His-E7), diluted 1:1000 was used for the detection (Figure 2), and by ELISA assay (Figure 3) in which a mouse polyclonal antibody against the E7-His protein, diluted 1:1000, was used for the detection. In particular  
10 the amount of E7 protein present in the extracts was accurately assessed by TAS-ELISA, using rabbit anti-E7 antibodies (see example 2).

No immunoreactive bands were detected in leaf extracts from plants infected with plasmid pPVX201 or PVX  
15 wild type virions, indicating the specificity of the preparation for the cloned antigen.

As evidence of the stability of the construct pPVX201-E7, high expression levels were detected in all plants at least until the fifth passage of infection with  
20 leaf extracts containing the recombinant virus.

The construct stability and the maintenance of the gene integrity, even after several reinfection passages, allowed an in-plant production of the E7 protein in an antigenically active form. This entails several  
25 advantages, e.g. the accumulation of the entire antigenic protein rather than a small epitope of it, as in the case of the display of protein portions at the surface of chimeric VLPs (virus like particles) in which regions able to induce a CTL response to E7 in mice are fused to  
30 the L1/L2 HPV proteins and used as vaccine of prophylactic/therapeutic type.

In particular, the plant-derived E7 proteins according to the process of the invention proved immunogenically similar in all to the E7-His protein  
35 derived from *E. coli*, with the advantage that in this case no purification was needed (Figure 4).

In particular, in experimental vaccination tests with PVX-E7 plant extracts, by subcutaneous administration and with no adjuvant addition, in animal models (mice) and subsequent challenge with a tumour line  
5 expressing E7, a protection from the tumour was obtained in about the 50% of the vaccinated mice (Figure 5).

The extracts can derive from foliar juices, upon extraction of the total soluble proteins with mild methods, as well as in an enriched form from the  
10 apoplast, upon extraction of the intercellular fluids by vacuum infiltration.

Said tissues and/or the partial purification products thereof, like the intercellular fluids, can be used for purification and tests of biological activity in  
15 animals.

Concerning the storing modes, for a short-time storage (e.g. of some days) the excised plants or leaves can be stored at room temperature or at + 4°C. The infected tissues (e.g., whole leaves) are still able to  
20 induce viral infection symptoms after a prolonged (more than one year) storing at -80°C. Alternatively, infected plant extracts can successfully yield new productive infections after storing at -20°C, even for relatively lengthy times (more than one month). The heterologous  
25 gene encoding the E7 protein is stably maintained during the infection stages of the virus and it seems not to interfere with its replication at least until the fifth reinfection passage, by mechanical infections, with infected juices. Also the expression level of the E7  
30 protein in the various passages is unchanged, at estimated values of about 100-150 ng of protein per 100 µl of extract, obtained as disclosed in the examples. Hence, the genetic stability of the construct is matched by a likewise stable expression level.

35 Concerning the stability of the E7 protein, said protein is present in the extracts even after storing at + 4°C for several days (more than 15), as demonstrated by



its reactivity in ELISA and in W. blot with a specific polyclonal serum.

The above crude extracts, administered to mice (several times, at intervals of about 15 days), in particular with 500 µl of extracts containing recombinant E7, as they are or with adjuvant (Quil-A), led to an effective immune response.

In particular, a certain number of immunized mice generated a specific CTL response, and even after 40 days were still tumour free.

80% of the vaccinated mice also developed an antibody response against the plant-produced E7 protein starting from the 4<sup>th</sup> immunization, even in the absence of adjuvant, and this response proved higher than that produced by the same extracts in the presence of adjuvant. Then, in a preliminary testing, the mice 'vaccinated' with the PVX-E7 extracts were injected with cells of a tumour line containing the gene E7 of HPV16, demonstrating protection from tumour challenge in about the 50% of the animals.

Also the presence of delayed hypersensitivity, measured through ear thickness micrometering of vaccinated mice at 24, 48, and 72 hours from antigen inoculation, was detected in a significant number of animals.

Hence, it was demonstrated that a vaccinogen can be expressed in plants at significant levels and that crude extracts can be used for vaccination purposes without purification and without adjuvants.

The preferred administration mode in the case of pathogens infecting the mucosal surfaces, like the HPV, is the oral one as the latter is particularly useful to induce both humoral and mucosal immunity (prophylactic vaccine).

For plant-produced HPV antigens, in particular for the E7 protein (therapeutic vaccine), the immunization scheme in model animals (mice) is based on the

subcutaneous administration of several doses of antigen, starting from crude leaf extracts. Likewise, the vaccination could be carried out with partially purified extracts or with the purified protein. Moreover, the immunization scheme could envisage different vaccinogen doses and administration at different times. The effectiveness of the immunization with plant extracts, compared to that carried out with the E7-His protein, in the presence of Quil-A as adjuvant, effective in the rejection of the E7-expressing tumours, demonstrates these vaccinal schemes to be equipotent.

Moreover, other routes of administration like the subcutaneous and the mucosal one can also influence the immune response to the plant extracts. The injection scheme, the dose to be injected and the administration route which generate the strongest humoral response or the strongest cell-mediated immunity are those detailed hereinafter.

Hereto, merely a general outline of the present invention has been provided. With the aid of the following examples, hereinafter a more detailed description of specific embodiments thereof will be provided, aimed at making better understood its aims, features, advantages and operation modes.

#### EXAMPLES

##### Example 1: Construction of a plasmid for the PVX-mediated expression

The HPV 16-E7 gene was amplified by PCR from the plasmid E7-pGEX-4T1 (Di Lonardo A., Marcante M. L., Poggiali F., Venuti A. (1998). 'HPV16 E7 antibody levels in cervical cancer patients: before and after treatment'. *Journal of Medical Virology* 54: 192-195) using as primers the oligonucleotides E7 For (5'GGC CAT CGA TTC TAG AC **ATG** CAT GGA GAT ACA CCT ACA CAT TG 3', sites for the enzymes Cla I and Xba I underlined, codon for Methionine bolded) and E7 Rev (5' GGC CGT CGA CCC C GGG **TTA** TGG TTT CTG AGA

ACA GAT GGG 3', sites for the enzymes Sal I and Sma I underlined, STOP codon bolded).

After digestion with the restriction enzymes Cla I and Sal I, the fragment was cloned in the vector pPVX201, obtaining the plasmid pPVX201-E7, which allows soluble expression of the E7 protein upon manual infection with the DNA plasmid (Figure 1).

After infection with DNA plasmid, *N. benthamiana* plants showing symptoms of infection were obtained 6-7 days post-inoculation. PVX-E7 extracts were also used for subsequent manual inoculation of fresh plants in order to study the stability of the construct.

Example 2: Preparation of plant extract and analysis of expression of E7 protein

E7 expression was analysed both by Western blot and ELISA. Plant soluble proteins were obtained by homogenization of leaves in a blender with liquid nitrogen. The resulting powder was resuspended (0.3 g of fresh leaf /ml buffer) in extraction buffer 1xPBS, containing protease inhibitors ('Complete, EDTA-free', Boehringer Mannheim). The extract was centrifuged 10 min at 12.000 g and supernatant collected. The proteins present in the plant extracts were separated by 12% SDS-PAGE and transferred by electroblotting onto PVDF filters. The presence of E7 protein was detected by using a mouse polyclonal serum obtained against the His-E7 purified from *E. coli*, diluted 1:1000, and subsequently a goat anti-mouse IgG conjugated with HRP. Reactions were developed with the ECL system (Amersham) (Figure 2).

PVX-E7 leaf extracts were used in order to determine the amount of total soluble protein (TSP) by using the Bradford assay (BioRad) and bovine serum albumin was used as a protein standard. The amount of E7 protein in the extracts was estimated by a triple antibody sandwich (TAS)-ELISA. A rabbit polyclonal antibody against E7 was diluted 1:500 in carbonate coating buffer, pH 9.6, and used for coating the ELISA plates for 2 hours at room

temperature. After blocking with 5% skimmed milk in PBS, 100  $\mu$ l of leaf extracts were added and incubated overnight at 4°C, utilising known amounts of E7 purified from bacteria for comparison. Then, the samples were incubated with a mouse anti His-E7 polyclonal antibody, diluted 1:1000 and detection was done with a goat anti-mouse antibody conjugated to Horseradish peroxidase (HRP) (Figure 3).

Example 3: Vaccine composition made of a plant extract to which the purified E7 protein is added.

The E7-His protein produced from *E. coli* and purified according to standard procedures (PVX-WT+E7) was added to plant extracts deriving from *N. benthamiana*, infected with the PVX wild type (PVX-WT), prepared according to the procedures described in example 2.

Systemic leaves showing typical symptoms of infection were subjected to total protein extraction in PBS buffer with and without protease inhibitors, according to the process described in example 2.

For a better characterisation, the foliar extracts of PVX-WT *N. benthamiana*, to which the purified His-E7 protein had been added from the outside at a final concentration of 8.3 ng/ $\mu$ l (PVX-WT+E7) in the extract, were kept at room temperature and at +4°C for 2 hours prior to analysis by Western blot and ELISA.

The results of the Western blot performed comparing the PVX-WT+E7 and the PVX-E7 extracts highlight the inexistence of significant differences between the two patterns. Moreover, the extracts exhibit a satisfactory and comparable ELISA activity.

Furthermore, no relevant difference was highlighted among the PVX-E7 patterns and the PVX-WT+E7 patterns obtained in the presence and in the absence of protease inhibitors. In the absence as well as in the presence of protease inhibitors both extracts exhibit a good ELISA reactivity (even after storing at +4°C for more than 25 days), whereas the inhibitor-free extracts anyhow exhibit

a reactivity sensibly improved with respect to the inhibitor-provided extracts.

Moreover, the related patterns are not affected by the incubation temperature, given a 2 hour incubation time.

Accordingly, the outside addition of the vaccinogen, and in particular of the E7, in a PVX-WT-infected plant extract results in a composition having properties comparable to those of a composition in which the vaccinogen is internally produced, according to the hereto exemplified procedures.

#### Example 4: Immunization of animals

PVX-E7-infected plant extracts (500 µl) and PVX-WT plant extracts (500 µl) to which E7-His protein produced from *E. coli* and purified (0.5 µg,) was added from the outside (PVX-WT+E7) were administered subcutaneously, with or without Quil-A as adjuvant, to C57BL/6 mice. Immunizations were repeated, at 15 days interval. As a control, several mice were immunized with the recombinant E7-His protein purified from *E. coli* plus Quil-A. 15 days after the final booster, animals were bled and the sera were analyzed for the presence of anti-E7 specific antibodies by ELISA. The results (Figure 4) show that the mice immunized with leaf extracts had developed anti-E7 antibodies, with no need of additional adjuvants.

#### Example 5: Tumour challenge

15 days after the final booster, the 'vaccinated' mice were challenged subcutaneously with  $4 \times 10^5$  cells of a syngeneic tumour line expressing E7 (C3). The CTL response was tested by ELISPOT. Briefly: 96-well filtration plates were coated with anti-mouse IFN  $\gamma$  antibody and incubated overnight, in order to capture the IFN- $\gamma$  secretion by these activated T cells. For detection of CD4 and CD8 cell precursors, splenocytes from vaccinated mice were harvested on day 14 after C3 challenge and added to the wells along with interleukin-2 (15 units/ml). Cells were incubated for 24 hours with or

without peptides representing E7-specific H-2D<sup>b</sup> CTL epitope (aa. 49-57). After culture, the plates were washed, incubated with biotinylated anti-mouse IFN $\gamma$  antibody, washed again and incubated with avidin-alkaline phosphatase. The reaction between the IFN- $\gamma$  and its antibody is highlighted by spots, developed with BCIP/NBT. Tumour mass in C3 challenged mice was measured too, in order to highlight a possible delay in the growth thereof.

10      Example 6: Determination of E7-specific antibodies

The presence of E7-specific IgG in the sera of mice immunized with the recombinant plant E7 protein was assayed by ELISA. 96-well polystyrene plates were coated overnight at 4°C with the E7-His protein (1  $\mu$ g/ml),  
15      diluted in carbonate buffer (50 mM NaHCO<sub>3</sub>, pH 9.6).

After blocking with a solution containing skimmed milk 5% in PBS for 2 hours, the sera of the immunized mice diluted 1:50 or 1:100 in a PBS 0.5% Tween-20 buffer were added to the samples.

20      Detection of total IgG and IgG2a subclass was performed by the respective biotin conjugate goat antimouse IgG. The signal was amplified by adding Horseradish peroxidase conjugate streptavidin (Southern Biotechnology Associates, Inc.). The reaction was  
25      developed by adding ABTS (2,2-azino-bis-benzthiazoline-6-sulfonic acid) solution (Southern Biotechnology Associates, Inc.). The optical density of the samples was determined at 405 nm using an ELISA reader.

30      Example 7: Comparison of E7 expression in several plant systems infected with PVX-E7 virion.

In order to evaluate the validity of systems different from the *N. benthamiana*, *Chenopodium quinoa* (fam. Chenopodiaceae), *Nicotiana benthamiana*, and *N. tabacum* (fam. Solanaceae) plants were infected with an  
35      extract of leaf juices derived from *N. benthamiana* infected with the plasmid pPVX201-E7.

Then an immunoblotting (extraction in PBS buffer with the addition of protease inhibitors as abovedescribed) and an ELISA were performed on systemic leaves, or on inoculated leaves of each plant according to the abovedescribed process.

The result highlighted:

a. *Systemic leaves*

- *N. benthamiana*: symptoms appeared 5-6 days after infection, in W. blot exhibiting the typical pattern hereto described and a good reactivity in in ACP (antigen coated plate) and in TAS-ELISA;

- *N. tabacum*: symptoms appeared about 9 days after infection. The W. Blot pattern is in all similar to that of *N. benthamiana*, and the reactivity in ELISA is significant (triple with respect to the blank) though weaker than that exhibited by *N. benthamiana*;

- *C. quinoa*: no symptoms, even one month after infection, along with an absence of signal for E7 in W. Blot and in ELISA;

b. *Inoculated leaves*

- *N. benthamiana*: symptoms appeared about 7-8 days after the infection. Both the W. Blot and the ELISA results respectively exhibit a pattern and a reactivity that are similar, though weaker, with respect to those observed for the systemic leaves;

- *N. tabacum*: symptoms appeared 7 days after infection. W. blot results highlight a pattern similar to that observed for the systemic leaves, with a band having the molecular weight of E7, though of reduced intensity. The reactivity in ELISA is significant, though weaker with respect to that of *N. benthamiana*;

- *C. quinoa*: clear symptoms appeared 6 days after infection. W. blot results highlight a very strong pattern, with a more intense band at a molecular weight corresponding to that of E7, absent in the wild type PVX-infected plants. The reactivity in ELISA is high, comparable to that of *N. benthamiana*.

These results demonstrate the relevance of the three systems for the purposes of the invention.

To the abovedescribed processes, uses, vectors, vaccines and plants a person skilled in the art, in order  
5 to satisfy further and contingent needs, could effect several further modifications and variants, all however encompassed by the protection scope of the present invention, as defined by the appended claims.



BIBLIOGRAPHICAL REFERENCES

- Baulcombe D. C., Chapman S., Santa Cruz S. (1995). 'Jellyfish green fluorescent protein as a reporter for virus infections'. *The Plant Journal* 7: 1045-1053.
- 5        - Breitburd F., Coursaget P. (1999). 'Human papillomavirus vaccines'. *Semin. Cancer Biol.* 9:431-444.
- Chapman S., Kavanagh T., Baulcombe D. (1992). 'Potato virus X as a vector for gene expression in plants'. *The Plant Journal* 2: 549-557.
- 10       - Di Lonardo A., Marcante M. L., Poggiali F., Venuti A. (1998). 'HPV16 E7 antibody levels in cervical cancer patients: before and after treatment'. *Journal of Medical Virology* 54: 192-195.
- Fernando G.J. P., Murray B., Zhou J., Frazer I. H. 15 (1999). 'Expression, purification and immunological characterisation of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16'. *Clin. Exp. Immunol.* 115: 397-403.
- Franconi R., Roggero P., Pirazzi P., Arias F. J., 20 Desiderio A., Bitti O., Pashkoulov D., Mattei B., Bracci L., Masenga V., Milne R. G., Benvenuto E. (1999). 'Functional expression in bacteria and in plants of an scFv antibody fragment against tospoviruses'. *Immunotechnology* 4: 189-201.
- 25       - Gupta, R. K. (1998). 'Aluminium compounds as vaccine'. *Advanced Drug Delivery Reviews* 32: 155-172.
- Hansson M., Nygren P.-A., Stahl S. (2000). 'Design and production of recombinant subunit vaccines' *Biotechnol. Appl. Biochem.* 32: 95-107.
- 30       - Hongxiu et al. (1999). *Human gene therapy* 10: 2727-2740.
- Singh M., O'Hagan D. (1999). 'Advances in vaccine adjuvants'. *Nature Biotechnology* 17: 1075-1081.
- Reinstein E, Scheffner M, Oren M et al (2000). 35 'Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue'. *Oncogene* 19:

5944-5950.

CLAIMS

1. Use of an extract of soluble proteins from leaf cells of a plant selected from the group comprising *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*, for the preparation of subunit vaccines comprising said extract as adjuvant along with a vaccinogen of interest.

2. Use according to claim 1, wherein said plant is *Nicotiana benthamiana*.

3. Vaccine comprising a vaccinogen of interest and as adjuvant an extract of soluble proteins from leaf cells of a plant selected from the group comprising *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*.

4. Vaccine according to claim 3, wherein said plant is *Nicotiana benthamiana*.

5. Vaccine according to claim 3 or 4, wherein said vaccinogen is a viral antigen.

6. Vaccine according to any one of claims 3 to 5, wherein said vaccinogen is the E7 protein of the human papillomavirus (HPV).

7. Vaccine according to any one of claims 3 to 6, obtainable by a process comprising the steps of:

a. expressing in soluble form a protein antigen in leaf cells of said plant at a concentration greater than or equal to 3µg of protein per gram of leaf; and

b. preparing an extract of total soluble proteins from said cells;

said plant extract being useful as subunit vaccine.

8. Vaccine according to claim 7, wherein the concentration of which at step a. is reached by transfection with a plant vector.

9. Vaccine according to claim 8, wherein said plant vector is a viral vector.

10. Vaccine according to claim 9, wherein said viral vector is derived from potato virus X (PVX).

11. Vaccine according to any one of claims 7 to 10, wherein step b. is carried out using extraction techniques of total soluble proteins such that said extraction is performed in the absence of detergents and of denaturing substances.

12. Process for the production of a subunit vaccine comprising the steps of:

a. expressing in soluble form a protein antigen in leaf cells of a plant selected from the group comprising *Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*, at a concentration greater than or equal to 3 µg of protein per gram of leaf; and

b. preparing an extract of total soluble proteins from said cells;

said plant extract being useful as subunit vaccine.

13. Process according to claim 12, wherein said plant is *Nicotiana benthamiana*.

14. Process according to claim 12 or 13, wherein said antigen is a viral antigen.

15. Process according to claim 14, wherein said antigen is the E7 protein of the human papillomavirus (HPV).

16. Process according to any one of claims 12 to 15, wherein the concentration of which at step a. is reached by transfection with a plant vector.

17. Process according to claim 16, wherein said plant vector is a viral vector.

18. Process according to claim 17, wherein said viral vector is derived from potato virus X (PVX).

19. Process according to any one of claims 12 to 18, wherein step b. is carried out using extraction techniques of total soluble proteins such that said extraction is performed in the absence of detergents and of denaturing substances.

20. Plant obtainable by the step of

a. expressing in soluble form a protein antigen in leaf cells of a plant selected from the group comprising

*Nicotiana benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*, at a concentration greater than or equal to 3 µg of protein per gram of leaf.

5 21. Plant according to claim 20, wherein said plant is *Nicotiana benthamiana*.

22. Plant according to claim 20 or 21, having foliar tissue with symptoms of infection, to which a high expression level of the heterologous protein is associated.

10 23. Plant according to any one of claims 20 to 22, wherein said protein antigen is provided by the HPV-E7 protein.

24. Process for the production of a vaccinogen comprising steps a. and b. as defined in claim 12 and the  
15 step of

c. purifying said vaccinogen from said extract.

25. Kit for the treatment of pathologies for the therapy of which it be necessary or advisable to induce an immune response of humoral as well as of cell-mediated  
20 type towards a determined vaccinogen comprising

- a composition comprising said vaccinogen along with compatible additives; and

- an extract of soluble proteins from leaf cells of a plant selected from the group comprising *Nicotiana*  
25 *benthamiana*, *Nicotiana tabacum* and *Chenopodium quinoa*;

for concomitant, sequential or separated use in the treatment of said pathologies.

26. Kit according to claim 25, wherein said plant is *Nicotiana benthamiana*.

30 27. Vaccines, processes, kit and uses, as previously described, exemplified and claimed.

pPVX201-E7




FIG.1




FIG.2

3/5




FIG.3



## specific anti-E7 IgGs in vaccinated mice





FIG.4

**FIG.5**

## INTERNATIONAL SEARCH REPORT

International application No

PCT/IT 02/00354

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/39 A61K39/12 C12N15/82 A01H5/00 A61P31/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 12801 A (THE TEXAS A & M UNIVERSITY SYSTEM) 2 May 1996 (1996-05-02) page 102 -page 108 ----	1,12, 20-27
X	WO 01 07613 A (LARGE SCALE BIOLOGY CORPORATION) 1 February 2001 (2001-02-01) the whole document ----	1,12, 20-27
A	GERARD C M ET AL: "Therapeutic potential of protein and adjuvant vaccinations on tumour growth" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 17-19, 21 March 2001 (2001-03-21), pages 2583-2589, XP004231084 ISSN: 0264-410X the whole document ---- -/--	1-27



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*8\* document member of the same patent family

Date of the actual completion of the international search

22 November 2002

Date of mailing of the international search report

28/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 02/00354

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KOPROWSKI H ET AL: "The green revolution: plants as heterologous expression vectors" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 17-19, 21 March 2001 (2001-03-21), pages 2735-2741, XP004231105 ISSN: 0264-410X the whole document	1-27
P,X	WO 01 66778 A (LARGE SCALE BIOLOGY CORPORATION) 13 September 2001 (2001-09-13) the whole document	1-27
P,X	WO 01 61022 A (GENOMINE) 23 August 2001 (2001-08-23) the whole document	1-27

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IT 02/00354

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9612801	A	02-05-1996	AU 691707 B2	21-05-1998
			AU 4194096 A	15-05-1996
			CA 2203679 A1	02-05-1996
			EP 0793717 A1	10-09-1997
			JP 10507916 T	04-08-1998
			NZ 297142 A	28-09-2001
			WO 9612801 A1	02-05-1996
			US 6194560 B1	27-02-2001
WO 0107613	A	01-02-2001	AU 6235000 A	13-02-2001
			WO 0107613 A2	01-02-2001
			US 2002164585 A1	07-11-2002
WO 0166778	A	13-09-2001	AU 4550901 A	17-09-2001
			WO 0166778 A2	13-09-2001
			US 2002061309 A1	23-05-2002
WO 0161022	A	23-08-2001	AU 2696700 A	27-08-2001
			WO 0161022 A1	23-08-2001
			US 6444805 B1	03-09-2002

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**